Journal of Comparative Effectiveness Research,
Journal Year:
2025,
Volume and Issue:
14(3)
Published: Feb. 19, 2025
Aim:
Screening
and
monitoring
of
diabetes
or
dyslipidemia
frequently
involves
a
multi-step
process
requiring
patients
to
obtain
test
requisitions
from
their
primary
care
physician
(PCP),
followed
by
laboratory
visit
re-consultation.
Point-of-care
testing
(POCT)
for
hemoglobin
A1c
(HbA1c)
lipid
panel
can
streamline
the
patient
pathway.
This
study
assessed
budget
impact
introducing
Afinion™
2
POCT
(Abbott
Rapid
Diagnostics)
Canadian
Italian
societal
perspectives.
Methods:
Budget
models
were
developed
Canada
Italy
over
5-year
time
horizon
(2025
2029).
The
analyses
considered
screening
utilizing
public
healthcare
system
attending
care,
included
direct
costs
(testing,
consultations)
indirect
(productivity
loss,
transportation)
based
on
published
sources.
(BI)
was
calculated
comparing
scenarios
with
without
POCT.
All
adjusted
dollars
($)
2024
Euros
(€).
Scenario
conducted
explore
alternative
assumptions.
Results:
cumulative
BI
-$758,006,692
(-$50,709,964
direct,
-$707,296,728
indirect)
HbA1c
-$726,452,755
($2,684,011
-$729,136,766
in
-€1,380,658,764
(-€6,391,954
-€1,374,266,809
-€851,792,115
(€55,962,879
-€907,754,993
Italy.
In
both
countries,
cost
savings
payer
observed
POCT,
while
derived
estimated
that
1,558,062
1,501,260
PCP
consultations
Canada,
4,962,338
1,951,026
avoided
implementation
panel,
respectively.
demonstrated
potential
further
pharmacies.
Conclusion:
demonstrates
adoption
Afinion
provide
efficiencies
different
types
systems
through
reducing
consultations,
saving
money
providing
payers.
International Journal of Clinical Practice,
Journal Year:
2022,
Volume and Issue:
2022, P. 1 - 10
Published: Jan. 31, 2022
Background.
Variability
of
HbA1c
has
been
related
to
the
incidence
micro
and
macrovascular
complications
in
patients
with
diabetes.
However,
association
between
visit-to-visit
variability
risk
dementia
not
fully
determined.
A
meta-analysis
was
performed
comprehensively
evaluate
above
association.
Methods.
Medline,
Embase,
Web
Science
databases
were
searched
for
longitudinal
follow-up
studies
comparing
diabetic
higher
or
lower
HbA1c.
random-effect
model
incorporating
potential
heterogeneity
among
included
used
pool
results.
Results.
Five
retrospective
577592
included,
99%
them
type
2
diabetes
mellitus
(T2DM).
With
a
mean
duration
6.3
years,
31963
had
newly
diagnosed
dementia.
Pooled
results
showed
that
associated
dementia,
as
evidenced
by
coefficient
variation
(CV:
hazard
ratio
(HR):
1.06;
95%
confidence
interval
(CI):
1.003–1.120;
;
I2
=
47%)
standard
deviation
(SD
:
HR:
1.19;
CI:
1.06–1.32;
id="M2">
0.002
0%)
continuous
variables,
CV
(HR:
1.18;
1.08–1.28;
id="M3">
<0.001
31%)
categorized
variables.
Conclusions.
Higher
is
Frontiers in Endocrinology,
Journal Year:
2022,
Volume and Issue:
13
Published: Aug. 31, 2022
Atherosclerosis
(AS)
is
a
chronic
inflammatory
disease
and
leading
cause
of
cardiovascular
diseases.
The
progression
AS
multi-step
process
to
high
morbidity
mortality.
Hyperglycemia,
dyslipidemia,
advanced
glycation
end
products
(AGEs),
inflammation
insulin
resistance
which
strictly
involved
in
diabetes
are
closely
related
the
pathogenesis
AS.
A
growing
number
studies
have
linked
AGEs
As
one
risk
factors
cardiac
metabolic
diseases,
dysfunction
VSMCs
plays
an
important
role
pathogenesis.
increased
diabetes,
participate
occurrence
through
multiple
molecular
mechanisms
vascular
cell
injury.
main
functional
cells
vascular,
smooth
muscle
(VSMCs)
play
different
roles
each
stage
atherosclerotic
lesions.
interaction
between
receptor
for
(RAGE)
accelerates
by
affecting
proliferation
migration
VSMCs.
In
addition,
increasing
researches
reported
that
promote
osteogenic
transformation
macrophage-like
VSMCs,
affect
other
aspects
such
as
autophagy
cycle.
this
review,
we
summarize
effect
on
plaque
development
progression.
We
also
discuss
link
mellitus,
including
oxidative
stress,
inflammation,
RAGE
ligands,
small
noncoding
RNAs.
Journal of Comparative Effectiveness Research,
Journal Year:
2025,
Volume and Issue:
14(3)
Published: Feb. 19, 2025
Aim:
Screening
and
monitoring
of
diabetes
or
dyslipidemia
frequently
involves
a
multi-step
process
requiring
patients
to
obtain
test
requisitions
from
their
primary
care
physician
(PCP),
followed
by
laboratory
visit
re-consultation.
Point-of-care
testing
(POCT)
for
hemoglobin
A1c
(HbA1c)
lipid
panel
can
streamline
the
patient
pathway.
This
study
assessed
budget
impact
introducing
Afinion™
2
POCT
(Abbott
Rapid
Diagnostics)
Canadian
Italian
societal
perspectives.
Methods:
Budget
models
were
developed
Canada
Italy
over
5-year
time
horizon
(2025
2029).
The
analyses
considered
screening
utilizing
public
healthcare
system
attending
care,
included
direct
costs
(testing,
consultations)
indirect
(productivity
loss,
transportation)
based
on
published
sources.
(BI)
was
calculated
comparing
scenarios
with
without
POCT.
All
adjusted
dollars
($)
2024
Euros
(€).
Scenario
conducted
explore
alternative
assumptions.
Results:
cumulative
BI
-$758,006,692
(-$50,709,964
direct,
-$707,296,728
indirect)
HbA1c
-$726,452,755
($2,684,011
-$729,136,766
in
-€1,380,658,764
(-€6,391,954
-€1,374,266,809
-€851,792,115
(€55,962,879
-€907,754,993
Italy.
In
both
countries,
cost
savings
payer
observed
POCT,
while
derived
estimated
that
1,558,062
1,501,260
PCP
consultations
Canada,
4,962,338
1,951,026
avoided
implementation
panel,
respectively.
demonstrated
potential
further
pharmacies.
Conclusion:
demonstrates
adoption
Afinion
provide
efficiencies
different
types
systems
through
reducing
consultations,
saving
money
providing
payers.
